What is the projected market valuation of the Schistosomiasis Treatment Market by 2035?

The Schistosomiasis Treatment Market is projected to reach 1.81 USD Billion by 2035. Read More

What was the market valuation of the Schistosomiasis Treatment Market in 2024?

In 2024, the market valuation was 1.064 USD Billion. Read More

What is the expected CAGR for the Schistosomiasis Treatment Market during the forecast period 2025 - 2035?

The expected CAGR for the Schistosomiasis Treatment Market during 2025 - 2035 is 4.95%. Read More

Which drug type generated the highest revenue in the Schistosomiasis Treatment Market?

Praziquantel generated the highest revenue, with a valuation range from 0.634 to 0.99 USD Billion. Read More

What are the key administration routes for Schistosomiasis treatments?

The key administration routes include Oral, Injectable, and Topical, with Oral treatments valued between 0.532 and 0.935 USD Billion. Read More

Which end user segment is expected to contribute the most to the Schistosomiasis Treatment Market?

Hospitals are expected to contribute the most, with a valuation range from 0.425 to 0.725 USD Billion. Read More

What is the revenue range for Oxamniquine in the Schistosomiasis Treatment Market?

Oxamniquine has a revenue range from 0.215 to 0.38 USD Billion. Read More

How does the revenue for long-term treatments compare to short-term treatments?

Both short-term and long-term treatments are projected to generate similar revenues, each ranging from 0.532 to 0.905 USD Billion. Read More

Who are the leading companies in the Schistosomiasis Treatment Market?

Key players include Merck & Co, Bristol-Myers Squibb, GlaxoSmithKline, and others. Read More

What is the revenue range for topical treatments in the Schistosomiasis Treatment Market?

Topical treatments are valued between 0.213 and 0.312 USD Billion. Read More

Schistosomiasis Treatment Market

ID: MRFR/HC/39661-HCR

100 Pages

Rahul Gotadki

Last Updated: April 06, 2026

Schistosomiasis Treatment Market Research Report By Drug Type (Praziquantel, Oxamniquine, Metrifonate, Other Drugs), By Administration Route (Oral, Injectable, Topical), By End User (Hospitals, Clinics, Pharmacies, Home Care Settings), By Treatment Duration (Short-term, Long-term) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth & Industry Forecast 2025 To 2035

Schistosomiasis Treatment Market Infographic

Summary Table of Contents Segmentation Download PDF

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Healthcare, BY Drug Type (USD Billion)
  1. 4.1.1 Praziquantel
  2. 4.1.2 Oxamniquine
  3. 4.1.3 Metrifonate
  4. 4.1.4 Other Drugs
2. 4.2 Healthcare, BY Administration Route (USD Billion)
  1. 4.2.1 Oral
  2. 4.2.2 Injectable
  3. 4.2.3 Topical
3. 4.3 Healthcare, BY End User (USD Billion)
  1. 4.3.1 Hospitals
  2. 4.3.2 Clinics
  3. 4.3.3 Pharmacies
  4. 4.3.4 Home Care Settings
4. 4.4 Healthcare, BY Treatment Duration (USD Billion)
  1. 4.4.1 Short-term
  2. 4.4.2 Long-term
5. 4.5 Healthcare, BY Region (USD Billion)
  1. 4.5.1 North America
    1. 4.5.1.1 US
    2. 4.5.1.2 Canada
  2. 4.5.2 Europe
    1. 4.5.2.1 Germany
    2. 4.5.2.2 UK
    3. 4.5.2.3 France
    4. 4.5.2.4 Russia
    5. 4.5.2.5 Italy
    6. 4.5.2.6 Spain
    7. 4.5.2.7 Rest of Europe
  3. 4.5.3 APAC
    1. 4.5.3.1 China
    2. 4.5.3.2 India
    3. 4.5.3.3 Japan
    4. 4.5.3.4 South Korea
    5. 4.5.3.5 Malaysia
    6. 4.5.3.6 Thailand
    7. 4.5.3.7 Indonesia
    8. 4.5.3.8 Rest of APAC
  4. 4.5.4 South America
    1. 4.5.4.1 Brazil
    2. 4.5.4.2 Mexico
    3. 4.5.4.3 Argentina
    4. 4.5.4.4 Rest of South America
  5. 4.5.5 MEA
    1. 4.5.5.1 GCC Countries
    2. 4.5.5.2 South Africa
    3. 4.5.5.3 Rest of MEA
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Healthcare
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Merck & Co (US)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Bristol-Myers Squibb (US)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 GlaxoSmithKline (GB)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Sanofi (FR)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Novartis (CH)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Pfizer (US)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 AstraZeneca (GB)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 Bayer (DE)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
  9. 5.2.9 Johnson & Johnson (US)
    1. 5.2.9.1 Financial Overview
    2. 5.2.9.2 Products Offered
    3. 5.2.9.3 Key Developments
    4. 5.2.9.4 SWOT Analysis
    5. 5.2.9.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 NORTH AMERICA MARKET ANALYSIS
3. 6.3 US MARKET ANALYSIS BY DRUG TYPE
4. 6.4 US MARKET ANALYSIS BY ADMINISTRATION ROUTE
5. 6.5 US MARKET ANALYSIS BY END USER
6. 6.6 US MARKET ANALYSIS BY TREATMENT DURATION
7. 6.7 CANADA MARKET ANALYSIS BY DRUG TYPE
8. 6.8 CANADA MARKET ANALYSIS BY ADMINISTRATION ROUTE
9. 6.9 CANADA MARKET ANALYSIS BY END USER
10. 6.10 CANADA MARKET ANALYSIS BY TREATMENT DURATION
11. 6.11 EUROPE MARKET ANALYSIS
12. 6.12 GERMANY MARKET ANALYSIS BY DRUG TYPE
13. 6.13 GERMANY MARKET ANALYSIS BY ADMINISTRATION ROUTE
14. 6.14 GERMANY MARKET ANALYSIS BY END USER
15. 6.15 GERMANY MARKET ANALYSIS BY TREATMENT DURATION
16. 6.16 UK MARKET ANALYSIS BY DRUG TYPE
17. 6.17 UK MARKET ANALYSIS BY ADMINISTRATION ROUTE
18. 6.18 UK MARKET ANALYSIS BY END USER
19. 6.19 UK MARKET ANALYSIS BY TREATMENT DURATION
20. 6.20 FRANCE MARKET ANALYSIS BY DRUG TYPE
21. 6.21 FRANCE MARKET ANALYSIS BY ADMINISTRATION ROUTE
22. 6.22 FRANCE MARKET ANALYSIS BY END USER
23. 6.23 FRANCE MARKET ANALYSIS BY TREATMENT DURATION
24. 6.24 RUSSIA MARKET ANALYSIS BY DRUG TYPE
25. 6.25 RUSSIA MARKET ANALYSIS BY ADMINISTRATION ROUTE
26. 6.26 RUSSIA MARKET ANALYSIS BY END USER
27. 6.27 RUSSIA MARKET ANALYSIS BY TREATMENT DURATION
28. 6.28 ITALY MARKET ANALYSIS BY DRUG TYPE
29. 6.29 ITALY MARKET ANALYSIS BY ADMINISTRATION ROUTE
30. 6.30 ITALY MARKET ANALYSIS BY END USER
31. 6.31 ITALY MARKET ANALYSIS BY TREATMENT DURATION
32. 6.32 SPAIN MARKET ANALYSIS BY DRUG TYPE
33. 6.33 SPAIN MARKET ANALYSIS BY ADMINISTRATION ROUTE
34. 6.34 SPAIN MARKET ANALYSIS BY END USER
35. 6.35 SPAIN MARKET ANALYSIS BY TREATMENT DURATION
36. 6.36 REST OF EUROPE MARKET ANALYSIS BY DRUG TYPE
37. 6.37 REST OF EUROPE MARKET ANALYSIS BY ADMINISTRATION ROUTE
38. 6.38 REST OF EUROPE MARKET ANALYSIS BY END USER
39. 6.39 REST OF EUROPE MARKET ANALYSIS BY TREATMENT DURATION
40. 6.40 APAC MARKET ANALYSIS
41. 6.41 CHINA MARKET ANALYSIS BY DRUG TYPE
42. 6.42 CHINA MARKET ANALYSIS BY ADMINISTRATION ROUTE
43. 6.43 CHINA MARKET ANALYSIS BY END USER
44. 6.44 CHINA MARKET ANALYSIS BY TREATMENT DURATION
45. 6.45 INDIA MARKET ANALYSIS BY DRUG TYPE
46. 6.46 INDIA MARKET ANALYSIS BY ADMINISTRATION ROUTE
47. 6.47 INDIA MARKET ANALYSIS BY END USER
48. 6.48 INDIA MARKET ANALYSIS BY TREATMENT DURATION
49. 6.49 JAPAN MARKET ANALYSIS BY DRUG TYPE
50. 6.50 JAPAN MARKET ANALYSIS BY ADMINISTRATION ROUTE
51. 6.51 JAPAN MARKET ANALYSIS BY END USER
52. 6.52 JAPAN MARKET ANALYSIS BY TREATMENT DURATION
53. 6.53 SOUTH KOREA MARKET ANALYSIS BY DRUG TYPE
54. 6.54 SOUTH KOREA MARKET ANALYSIS BY ADMINISTRATION ROUTE
55. 6.55 SOUTH KOREA MARKET ANALYSIS BY END USER
56. 6.56 SOUTH KOREA MARKET ANALYSIS BY TREATMENT DURATION
57. 6.57 MALAYSIA MARKET ANALYSIS BY DRUG TYPE
58. 6.58 MALAYSIA MARKET ANALYSIS BY ADMINISTRATION ROUTE
59. 6.59 MALAYSIA MARKET ANALYSIS BY END USER
60. 6.60 MALAYSIA MARKET ANALYSIS BY TREATMENT DURATION
61. 6.61 THAILAND MARKET ANALYSIS BY DRUG TYPE
62. 6.62 THAILAND MARKET ANALYSIS BY ADMINISTRATION ROUTE
63. 6.63 THAILAND MARKET ANALYSIS BY END USER
64. 6.64 THAILAND MARKET ANALYSIS BY TREATMENT DURATION
65. 6.65 INDONESIA MARKET ANALYSIS BY DRUG TYPE
66. 6.66 INDONESIA MARKET ANALYSIS BY ADMINISTRATION ROUTE
67. 6.67 INDONESIA MARKET ANALYSIS BY END USER
68. 6.68 INDONESIA MARKET ANALYSIS BY TREATMENT DURATION
69. 6.69 REST OF APAC MARKET ANALYSIS BY DRUG TYPE
70. 6.70 REST OF APAC MARKET ANALYSIS BY ADMINISTRATION ROUTE
71. 6.71 REST OF APAC MARKET ANALYSIS BY END USER
72. 6.72 REST OF APAC MARKET ANALYSIS BY TREATMENT DURATION
73. 6.73 SOUTH AMERICA MARKET ANALYSIS
74. 6.74 BRAZIL MARKET ANALYSIS BY DRUG TYPE
75. 6.75 BRAZIL MARKET ANALYSIS BY ADMINISTRATION ROUTE
76. 6.76 BRAZIL MARKET ANALYSIS BY END USER
77. 6.77 BRAZIL MARKET ANALYSIS BY TREATMENT DURATION
78. 6.78 MEXICO MARKET ANALYSIS BY DRUG TYPE
79. 6.79 MEXICO MARKET ANALYSIS BY ADMINISTRATION ROUTE
80. 6.80 MEXICO MARKET ANALYSIS BY END USER
81. 6.81 MEXICO MARKET ANALYSIS BY TREATMENT DURATION
82. 6.82 ARGENTINA MARKET ANALYSIS BY DRUG TYPE
83. 6.83 ARGENTINA MARKET ANALYSIS BY ADMINISTRATION ROUTE
84. 6.84 ARGENTINA MARKET ANALYSIS BY END USER
85. 6.85 ARGENTINA MARKET ANALYSIS BY TREATMENT DURATION
86. 6.86 REST OF SOUTH AMERICA MARKET ANALYSIS BY DRUG TYPE
87. 6.87 REST OF SOUTH AMERICA MARKET ANALYSIS BY ADMINISTRATION ROUTE
88. 6.88 REST OF SOUTH AMERICA MARKET ANALYSIS BY END USER
89. 6.89 REST OF SOUTH AMERICA MARKET ANALYSIS BY TREATMENT DURATION
90. 6.90 MEA MARKET ANALYSIS
91. 6.91 GCC COUNTRIES MARKET ANALYSIS BY DRUG TYPE
92. 6.92 GCC COUNTRIES MARKET ANALYSIS BY ADMINISTRATION ROUTE
93. 6.93 GCC COUNTRIES MARKET ANALYSIS BY END USER
94. 6.94 GCC COUNTRIES MARKET ANALYSIS BY TREATMENT DURATION
95. 6.95 SOUTH AFRICA MARKET ANALYSIS BY DRUG TYPE
96. 6.96 SOUTH AFRICA MARKET ANALYSIS BY ADMINISTRATION ROUTE
97. 6.97 SOUTH AFRICA MARKET ANALYSIS BY END USER
98. 6.98 SOUTH AFRICA MARKET ANALYSIS BY TREATMENT DURATION
99. 6.99 REST OF MEA MARKET ANALYSIS BY DRUG TYPE
100. 6.100 REST OF MEA MARKET ANALYSIS BY ADMINISTRATION ROUTE
101. 6.101 REST OF MEA MARKET ANALYSIS BY END USER
102. 6.102 REST OF MEA MARKET ANALYSIS BY TREATMENT DURATION
103. 6.103 KEY BUYING CRITERIA OF HEALTHCARE
104. 6.104 RESEARCH PROCESS OF MRFR
105. 6.105 DRO ANALYSIS OF HEALTHCARE
106. 6.106 DRIVERS IMPACT ANALYSIS: HEALTHCARE
107. 6.107 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
108. 6.108 SUPPLY / VALUE CHAIN: HEALTHCARE
109. 6.109 HEALTHCARE, BY DRUG TYPE, 2024 (% SHARE)
110. 6.110 HEALTHCARE, BY DRUG TYPE, 2024 TO 2035 (USD Billion)
111. 6.111 HEALTHCARE, BY ADMINISTRATION ROUTE, 2024 (% SHARE)
112. 6.112 HEALTHCARE, BY ADMINISTRATION ROUTE, 2024 TO 2035 (USD Billion)
113. 6.113 HEALTHCARE, BY END USER, 2024 (% SHARE)
114. 6.114 HEALTHCARE, BY END USER, 2024 TO 2035 (USD Billion)
115. 6.115 HEALTHCARE, BY TREATMENT DURATION, 2024 (% SHARE)
116. 6.116 HEALTHCARE, BY TREATMENT DURATION, 2024 TO 2035 (USD Billion)
117. 6.117 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 North America MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY DRUG TYPE, 2025-2035 (USD Billion)
  2. 7.2.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  3. 7.2.3 BY END USER, 2025-2035 (USD Billion)
  4. 7.2.4 BY TREATMENT DURATION, 2025-2035 (USD Billion)
2. 7.3 US MARKET SIZE ESTIMATES; FORECAST
  1. 7.3.1 BY DRUG TYPE, 2025-2035 (USD Billion)
  2. 7.3.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  3. 7.3.3 BY END USER, 2025-2035 (USD Billion)
  4. 7.3.4 BY TREATMENT DURATION, 2025-2035 (USD Billion)
3. 7.4 Canada MARKET SIZE ESTIMATES; FORECAST
  1. 7.4.1 BY DRUG TYPE, 2025-2035 (USD Billion)
  2. 7.4.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  3. 7.4.3 BY END USER, 2025-2035 (USD Billion)
  4. 7.4.4 BY TREATMENT DURATION, 2025-2035 (USD Billion)
4. 7.5 Europe MARKET SIZE ESTIMATES; FORECAST
  1. 7.5.1 BY DRUG TYPE, 2025-2035 (USD Billion)
  2. 7.5.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  3. 7.5.3 BY END USER, 2025-2035 (USD Billion)
  4. 7.5.4 BY TREATMENT DURATION, 2025-2035 (USD Billion)
5. 7.6 Germany MARKET SIZE ESTIMATES; FORECAST
  1. 7.6.1 BY DRUG TYPE, 2025-2035 (USD Billion)
  2. 7.6.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  3. 7.6.3 BY END USER, 2025-2035 (USD Billion)
  4. 7.6.4 BY TREATMENT DURATION, 2025-2035 (USD Billion)
6. 7.7 UK MARKET SIZE ESTIMATES; FORECAST
  1. 7.7.1 BY DRUG TYPE, 2025-2035 (USD Billion)
  2. 7.7.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  3. 7.7.3 BY END USER, 2025-2035 (USD Billion)
  4. 7.7.4 BY TREATMENT DURATION, 2025-2035 (USD Billion)
7. 7.8 France MARKET SIZE ESTIMATES; FORECAST
  1. 7.8.1 BY DRUG TYPE, 2025-2035 (USD Billion)
  2. 7.8.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  3. 7.8.3 BY END USER, 2025-2035 (USD Billion)
  4. 7.8.4 BY TREATMENT DURATION, 2025-2035 (USD Billion)
8. 7.9 Russia MARKET SIZE ESTIMATES; FORECAST
  1. 7.9.1 BY DRUG TYPE, 2025-2035 (USD Billion)
  2. 7.9.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  3. 7.9.3 BY END USER, 2025-2035 (USD Billion)
  4. 7.9.4 BY TREATMENT DURATION, 2025-2035 (USD Billion)
9. 7.10 Italy MARKET SIZE ESTIMATES; FORECAST
  1. 7.10.1 BY DRUG TYPE, 2025-2035 (USD Billion)
  2. 7.10.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  3. 7.10.3 BY END USER, 2025-2035 (USD Billion)
  4. 7.10.4 BY TREATMENT DURATION, 2025-2035 (USD Billion)
10. 7.11 Spain MARKET SIZE ESTIMATES; FORECAST
  1. 7.11.1 BY DRUG TYPE, 2025-2035 (USD Billion)
  2. 7.11.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  3. 7.11.3 BY END USER, 2025-2035 (USD Billion)
  4. 7.11.4 BY TREATMENT DURATION, 2025-2035 (USD Billion)
11. 7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST
  1. 7.12.1 BY DRUG TYPE, 2025-2035 (USD Billion)
  2. 7.12.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  3. 7.12.3 BY END USER, 2025-2035 (USD Billion)
  4. 7.12.4 BY TREATMENT DURATION, 2025-2035 (USD Billion)
12. 7.13 APAC MARKET SIZE ESTIMATES; FORECAST
  1. 7.13.1 BY DRUG TYPE, 2025-2035 (USD Billion)
  2. 7.13.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  3. 7.13.3 BY END USER, 2025-2035 (USD Billion)
  4. 7.13.4 BY TREATMENT DURATION, 2025-2035 (USD Billion)
13. 7.14 China MARKET SIZE ESTIMATES; FORECAST
  1. 7.14.1 BY DRUG TYPE, 2025-2035 (USD Billion)
  2. 7.14.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  3. 7.14.3 BY END USER, 2025-2035 (USD Billion)
  4. 7.14.4 BY TREATMENT DURATION, 2025-2035 (USD Billion)
14. 7.15 India MARKET SIZE ESTIMATES; FORECAST
  1. 7.15.1 BY DRUG TYPE, 2025-2035 (USD Billion)
  2. 7.15.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  3. 7.15.3 BY END USER, 2025-2035 (USD Billion)
  4. 7.15.4 BY TREATMENT DURATION, 2025-2035 (USD Billion)
15. 7.16 Japan MARKET SIZE ESTIMATES; FORECAST
  1. 7.16.1 BY DRUG TYPE, 2025-2035 (USD Billion)
  2. 7.16.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  3. 7.16.3 BY END USER, 2025-2035 (USD Billion)
  4. 7.16.4 BY TREATMENT DURATION, 2025-2035 (USD Billion)
16. 7.17 South Korea MARKET SIZE ESTIMATES; FORECAST
  1. 7.17.1 BY DRUG TYPE, 2025-2035 (USD Billion)
  2. 7.17.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  3. 7.17.3 BY END USER, 2025-2035 (USD Billion)
  4. 7.17.4 BY TREATMENT DURATION, 2025-2035 (USD Billion)
17. 7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST
  1. 7.18.1 BY DRUG TYPE, 2025-2035 (USD Billion)
  2. 7.18.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  3. 7.18.3 BY END USER, 2025-2035 (USD Billion)
  4. 7.18.4 BY TREATMENT DURATION, 2025-2035 (USD Billion)
18. 7.19 Thailand MARKET SIZE ESTIMATES; FORECAST
  1. 7.19.1 BY DRUG TYPE, 2025-2035 (USD Billion)
  2. 7.19.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  3. 7.19.3 BY END USER, 2025-2035 (USD Billion)
  4. 7.19.4 BY TREATMENT DURATION, 2025-2035 (USD Billion)
19. 7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST
  1. 7.20.1 BY DRUG TYPE, 2025-2035 (USD Billion)
  2. 7.20.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  3. 7.20.3 BY END USER, 2025-2035 (USD Billion)
  4. 7.20.4 BY TREATMENT DURATION, 2025-2035 (USD Billion)
20. 7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST
  1. 7.21.1 BY DRUG TYPE, 2025-2035 (USD Billion)
  2. 7.21.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  3. 7.21.3 BY END USER, 2025-2035 (USD Billion)
  4. 7.21.4 BY TREATMENT DURATION, 2025-2035 (USD Billion)
21. 7.22 South America MARKET SIZE ESTIMATES; FORECAST
  1. 7.22.1 BY DRUG TYPE, 2025-2035 (USD Billion)
  2. 7.22.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  3. 7.22.3 BY END USER, 2025-2035 (USD Billion)
  4. 7.22.4 BY TREATMENT DURATION, 2025-2035 (USD Billion)
22. 7.23 Brazil MARKET SIZE ESTIMATES; FORECAST
  1. 7.23.1 BY DRUG TYPE, 2025-2035 (USD Billion)
  2. 7.23.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  3. 7.23.3 BY END USER, 2025-2035 (USD Billion)
  4. 7.23.4 BY TREATMENT DURATION, 2025-2035 (USD Billion)
23. 7.24 Mexico MARKET SIZE ESTIMATES; FORECAST
  1. 7.24.1 BY DRUG TYPE, 2025-2035 (USD Billion)
  2. 7.24.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  3. 7.24.3 BY END USER, 2025-2035 (USD Billion)
  4. 7.24.4 BY TREATMENT DURATION, 2025-2035 (USD Billion)
24. 7.25 Argentina MARKET SIZE ESTIMATES; FORECAST
  1. 7.25.1 BY DRUG TYPE, 2025-2035 (USD Billion)
  2. 7.25.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  3. 7.25.3 BY END USER, 2025-2035 (USD Billion)
  4. 7.25.4 BY TREATMENT DURATION, 2025-2035 (USD Billion)
25. 7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST
  1. 7.26.1 BY DRUG TYPE, 2025-2035 (USD Billion)
  2. 7.26.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  3. 7.26.3 BY END USER, 2025-2035 (USD Billion)
  4. 7.26.4 BY TREATMENT DURATION, 2025-2035 (USD Billion)
26. 7.27 MEA MARKET SIZE ESTIMATES; FORECAST
  1. 7.27.1 BY DRUG TYPE, 2025-2035 (USD Billion)
  2. 7.27.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  3. 7.27.3 BY END USER, 2025-2035 (USD Billion)
  4. 7.27.4 BY TREATMENT DURATION, 2025-2035 (USD Billion)
27. 7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST
  1. 7.28.1 BY DRUG TYPE, 2025-2035 (USD Billion)
  2. 7.28.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  3. 7.28.3 BY END USER, 2025-2035 (USD Billion)
  4. 7.28.4 BY TREATMENT DURATION, 2025-2035 (USD Billion)
28. 7.29 South Africa MARKET SIZE ESTIMATES; FORECAST
  1. 7.29.1 BY DRUG TYPE, 2025-2035 (USD Billion)
  2. 7.29.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  3. 7.29.3 BY END USER, 2025-2035 (USD Billion)
  4. 7.29.4 BY TREATMENT DURATION, 2025-2035 (USD Billion)
29. 7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST
  1. 7.30.1 BY DRUG TYPE, 2025-2035 (USD Billion)
  2. 7.30.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  3. 7.30.3 BY END USER, 2025-2035 (USD Billion)
  4. 7.30.4 BY TREATMENT DURATION, 2025-2035 (USD Billion)
30. 7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.31.1
1. 7.32 ACQUISITION/PARTNERSHIP
7.32.1

Certified Researchers

Customize Report

Healthcare Market Segmentation

Healthcare By Drug Type (USD Billion, 2025-2035)

Praziquantel
Oxamniquine
Metrifonate
Other Drugs

Healthcare By Administration Route (USD Billion, 2025-2035)

Oral
Injectable
Topical

Healthcare By End User (USD Billion, 2025-2035)

Hospitals
Clinics
Pharmacies
Home Care Settings

Healthcare By Treatment Duration (USD Billion, 2025-2035)

Short-term
Long-term

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”

Rob Kooiker Group Product Manager HVAC & Fire Protection GMA

“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”

Akif Moroglu Strategy & Business Development Director

Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035

Features	License Type
Features	Single User	Multiuser License	Enterprise User
Price	$4,950	$5,950	$7,250
Maximum User Access Limit	1 User	Upto 10 Users	Unrestricted Access Throughout the Organization
Free Customization	✓	✓	✓
Direct Access to Analyst	✓	✓	✓
Deliverable Format	✓	✓	✓
Platform Access	✗	✗	✓
Discount on Next Purchase	10%	15%	15%
Printable Versions	✗	✗	✓